RAPT - Company ID 0001673772
The table below shows RAPT Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $1.53M | $3.81M | $5.04M | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $107.22M | $101.00M | $67.08M | $56.98M | $45.48M | $34.91M |
| SG&A |
RAPT Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2023. That is down 100.0% from $1.53M in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $28.88M |
| $26.06M |
| $20.24M |
| $16.04M |
| $12.77M |
| $8.72M |
| Operating income | -$136.10M | -$127.06M | -$85.80M | -$69.21M | -$53.21M | -$43.63M |
| Income tax | - | - | - | - | $990.00K | $660.00K |
| Net income | -$129.87M | -$116.80M | -$83.84M | -$69.20M | -$52.89M | -$43.00M |
| EPS (diluted) | -$3.19 | -$3.05 | -$2.58 | -$2.53 | - | - |